Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Rohypnol

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Flunitrazepam Testmiljö

Flunitrazepam

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Ban L, West J, Gibson JE, Fiaschi L, Sokal R, Doyle P et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One. 2014;9:e100996.

  2. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35:3-8.

  3. Dolovich LR, Addis A, Vaillancourt JM et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-43.

  4. Bonnot O, Vollset SE, Godet PF, d'Amato T, Dalery J, Robert E. In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam? Encephale 2003;29:553-9.

  5. Wikner BN, Stiller CO, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf. 2007;16:988-94.

  6. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203-10.

  7. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002;101:147-54.

  8. Ornoy A, Arnon J, Shechtman S et al. Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol 1998;12:511-5.

  9. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 1992;23:18-23.

  10. Laegreid L, Olegård R, Wahlström J et al. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987;1:108-9.

  11. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.

  12. Grigoriadis S, Graves L, Peer M, Mamisashvili L, Ruthirakuhan M, Chan P et al. Pregnancy and Delivery Outcomes Following Benzodiazepine Exposure: A Systematic Review and Meta-analysis. Can J Psychiatry. 2020;65(12):821-834.

  13. Grigoriadis S, Graves L, Peer M, Mamisashvili L, Dennis CL, Vigod SN et al. Benzodiazepine Use During Pregnancy Alone or in Combination With an Antidepressant and Congenital Malformations: Systematic Review and Meta-Analysis. J Clin Psychiatry. 2019;80(4):18r12412.

  14. Brandlistuen RE, Ystrom E, Hernandez-Diaz S, Skurtveit S, Selmer R, Handal M et al. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS One. 2017;12(7):e0181042.

  15. Sundbakk LM, Wood M, Gran JM, Nordeng H. Impact of prenatal exposure to benzodiazepines and z-hypnotics on behavioral problems at 5 years of age: A study from the Norwegian Mother and Child Cohort Study. PLoS One. 2019;14(6):e0217830.

  16. Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng H. Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers. JAMA Netw Open. 2019;2(4):e191435.

  17. Noh Y, Lee H, Choi A, Kwon JS, Choe SA, Chae J et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. PLoS Med. 2022;19(3):e1003945.

  1. Ban L, West J, Gibson JE, Fiaschi L, Sokal R, Doyle P et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One. 2014;9:e100996.
  2. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35:3-8.
  3. Dolovich LR, Addis A, Vaillancourt JM et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-43.
  4. Bonnot O, Vollset SE, Godet PF, d'Amato T, Dalery J, Robert E. In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam? Encephale 2003;29:553-9.
  5. Wikner BN, Stiller CO, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf. 2007;16:988-94.
  6. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203-10.
  7. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002;101:147-54.
  8. Ornoy A, Arnon J, Shechtman S et al. Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol 1998;12:511-5.
  9. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 1992;23:18-23.
  10. Laegreid L, Olegård R, Wahlström J et al. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987;1:108-9.
  11. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.
  12. Grigoriadis S, Graves L, Peer M, Mamisashvili L, Ruthirakuhan M, Chan P et al. Pregnancy and Delivery Outcomes Following Benzodiazepine Exposure: A Systematic Review and Meta-analysis. Can J Psychiatry. 2020;65(12):821-834.
  13. Grigoriadis S, Graves L, Peer M, Mamisashvili L, Dennis CL, Vigod SN et al. Benzodiazepine Use During Pregnancy Alone or in Combination With an Antidepressant and Congenital Malformations: Systematic Review and Meta-Analysis. J Clin Psychiatry. 2019;80(4):18r12412.
  14. Brandlistuen RE, Ystrom E, Hernandez-Diaz S, Skurtveit S, Selmer R, Handal M et al. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS One. 2017;12(7):e0181042.
  15. Sundbakk LM, Wood M, Gran JM, Nordeng H. Impact of prenatal exposure to benzodiazepines and z-hypnotics on behavioral problems at 5 years of age: A study from the Norwegian Mother and Child Cohort Study. PLoS One. 2019;14(6):e0217830.
  16. Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng H. Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers. JAMA Netw Open. 2019;2(4):e191435.
  17. Noh Y, Lee H, Choi A, Kwon JS, Choe SA, Chae J et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. PLoS Med. 2022;19(3):e1003945.